RAPT Therapeutics Announces Proposed Offering of Common Stock
February 04, 2020 17:42 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 07, 2020 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics to be Added to the Russell 2000® and Russell Microcap® Indices
December 16, 2019 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights
December 11, 2019 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors
December 10, 2019 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer
December 04, 2019 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia
December 03, 2019 16:05 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and SEOUL, South Korea, Dec. 03, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on...
CORRECTING and REPLACING -- FLX Bio to Present Poster at the American Association of Cancer Research (AACR) Conference on its Lead Immuno-Oncology Program Targeting CCR4
March 31, 2017 15:44 ET
|
FLX Bio
In a release issued under the same headline earlier today by FLX Bio, Inc., please note that the link to the abstract title under the Abstract information section was incorrect and has...
FLX Bio to Present Poster at the American Association of Cancer Research (AACR) Conference on its Lead Immuno-Oncology Program Targeting CCR4
March 31, 2017 11:00 ET
|
FLX Bio
SOUTH SAN FRANCISCO, Calif., March 31, 2017 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology (IO) agents and...
FLX Bio, Inc. Appoints Linda Kozick to its Board of Directors
December 12, 2016 12:42 ET
|
FLX Bio
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology agents, announced today...